Closed PAR-25-083 CFDA 93.399 Discretionary

Co-infection and Cancer (R21 Clinical Trial Not Allowed)

Posted by National Institutes of Health

Opportunity snapshot. This Grants.gov announcement — Co-infection and Cancer (R21 Clinical Trial Not Allowed) — is cataloged under number PAR-25-083 and tied to CFDA assistance listing 93.399, posted by National Institutes of Health. Grants.gov currently shows the opportunity as closed, first posted on November 21, 2024. The funding category is Discretionary, delivered as a grant.

Award economics. The award range on file is Varies by applicant. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.

Deadline and action path. This opportunity closed on January 7, 2026. Future funding cycles may be published under the same CFDA number, so monitoring the parent program page is the most reliable way to catch re-announcements. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully — federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed — it helps clarify scope and scoring priorities.

Award Range

Varies by applicant

Close Date

January 7, 2026

Posted

November 21, 2024

Instrument

Grant

Description

The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection and cancer to shed light on presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents either concurrently or sequentially and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and of co-infections that engender novel opportunities for prevention and treatment.

Eligibility

00;01;02;04;05;06;07;08;11;12;13;20;22;23;25

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

NIH Grants Information<br/>grantsinfo@nih.gov

Key Dates

Posted November 21, 2024
Close Date January 7, 2026
Archive Date February 12, 2026
Last Updated November 21, 2024

Frequently Asked Questions

What is this grant opportunity?
This is a federal funding opportunity titled "Co-infection and Cancer (R21 Clinical Trial Not Allowed)", offered by National Institutes of Health. It is associated with CFDA program 93.399. The purpose of this Funding Opportunity Announcement (FOA) is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection and cancer to shed light on presently unestab...
Is this opportunity still open?
No, this opportunity is closed. It closed on January 7, 2026. Check the parent program page for future funding cycles.
How much funding is available?
The award range for this opportunity is Varies by applicant.
How do I apply?
Applications for federal grant opportunities are typically submitted through Grants.gov. Visit the official listing at grants.gov for application instructions, required documents, and submission deadlines.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainGrants Editorial